IDAAPM: integrated database of ADMET and adverse effects of predictive modeling based on FDA approved drug data
- 2.3k Downloads
The disposition of a pharmaceutical compound within an organism, i.e. its Absorption, Distribution, Metabolism, Excretion, Toxicity (ADMET) properties and adverse effects, critically affects late stage failure of drug candidates and has led to the withdrawal of approved drugs. Computational methods are effective approaches to reduce the number of safety issues by analyzing possible links between chemical structures and ADMET or adverse effects, but this is limited by the size, quality, and heterogeneity of the data available from individual sources. Thus, large, clean and integrated databases of approved drug data, associated with fast and efficient predictive tools are desirable early in the drug discovery process.
We have built a relational database (IDAAPM) to integrate available approved drug data such as drug approval information, ADMET and adverse effects, chemical structures and molecular descriptors, targets, bioactivity and related references. The database has been coupled with a searchable web interface and modern data analytics platform (KNIME) to allow data access, data transformation, initial analysis and further predictive modeling. Data were extracted from FDA resources and supplemented from other publicly available databases. Currently, the database contains information regarding about 19,226 FDA approval applications for 31,815 products (small molecules and biologics) with their approval history, 2505 active ingredients, together with as many ADMET properties, 1629 molecular structures, 2.5 million adverse effects and 36,963 experimental drug-target bioactivity data.
KeywordsFDA approved drugs ADMET Adverse effects Targets Database Predictive modeling Drug-target database Data analysis
Absorption, Distribution, Metabolism, Excretion, Toxicity (ADMET) properties and adverse effects are considered to be responsible for the late stage failure of many promising compounds as well as for the withdrawal of approved drug molecules. Despite considerable efforts to improve the pharmacokinetic profiles of small-molecule drug candidates, overall attrition rates remain high mainly due to efficacy, safety issues, and selection of inappropriate drug targets [1, 2, 3].
Computational prediction of ADMET properties and adverse effects is an effective method to minimize the risk of late-stage attrition and reduce the number of safety issues. This method is now well established as a reliable and cost-effective approach to assist the drug discovery process. Computational models are used to focus medicinal chemistry efforts into the suitable chemical space; to connect, use and extend experimental data; to minimize the number of compounds to be synthesized; as well as to obtain a favorable biochemical and/or physicochemical profile [4, 5, 6, 7, 8, 9, 10, 11, 12]. For example, multiple studies have explored the benefit of controlling the size, lipophilicity and polarity properties of compounds in terms of reduced likelihood of attrition [4, 5, 6, 7, 8, 13, 14, 15].
Currently, a large amount of data is made available by the pharmaceutical industry and academic research groups that can be used for computational predictions. These data have been deposited in databases, among which the most well-established and freely accessible are DrugBank , ChEMBL , BindingDB , PubChem , PDB , PDBbind , GtoPdb , Therapeutic Target Database  and ChemIDPlus . DrugBank integrates detailed chemical, pharmacological and pharmaceutical drug data with target information. ChEMBL contains the chemical structures and bioactivity data of compounds with drug-like properties. BindingDB and PDBbind provides ligand–target interaction experimental affinity data that are mainly collected from scientific literature and other auxiliary databases such as ChEMBL. GtoPdb (previously IUPHAR-DB) contains ligand information and special sections for receptors, ion channels, kinases and transporters. Therapeutic Target Database (TTD) provides information about the known and explored therapeutic protein and nucleic acid targets such as disease, pathway and drugs connected to each of these targets. ChemIDPlus focus more on molecular and structural information of compounds. The US food and drug administration (FDA) has two publicly available databases; Drugs@FDA  which is the main resource that provides FDA-approved drug information, and FAERS (FDA adverse event reporting system), which contains a collection of reported post-marketed adverse effects [26, 27].
Focused and integrated databases with predictive ADMET and adverse effects models have been developed to exploit this data. UCSF-FDA TransPortal  focus on interaction of drug molecules with transporters, leading to drug–drug interactions. For example, Sedykh et al. collected and published a large collection of transporter interaction data for small molecules focused on major human intestinal transporters with the aim of building predictive models . Moda et al.  developed a database, PK/DB associated with five in silico ADME models to predict human intestinal absorption, human oral bioavailability, plasma protein binding, blood-brain barrier and water solubility. Kuhn et al. have developed a database called SIDER , which contains adverse effects of drugs and their frequency, however, unlike FAERS which is a reporting system, SIDER extracts the causal relation from the drug label. In another recent study, Cheng and coworkers developed a meta-database of drug adverse effects, MetaADEDB, which includes the SIDER data .
Although these resources possess an already large amount of ADMET or adverse effects data, they all have different aims and contents. Consequently, they do not integrate additional related data (e.g. approval application, affinity data, molecular descriptors, data references, adverse effects) and metadata required for in-depth predictive modeling analyses. It therefore requires tedious data preparation and cleaning to exploit these data for predictive modeling of ADMET properties or adverse effects. Therefore, a unified approved drugs information database, combined with fast and efficient predictive tools is desirable.
Here we describe IDAAPM, a publicly available database of FDA approved drugs, which have been developed as a useful resource for computational analyses and modeling. IDAAPM aims to bridge the gap by providing, in a single resource, integrated detailed information on approved drugs (small molecules and biologics) such as FDA application data, structures, molecular descriptors, ADMET properties and adverse effects, target and also related bioactivity data that are often missing in other comparable databases. This resource can be used to analyze relevant information across studies based on compound similarities and the chemical space associated with drug molecules. It would become possible to easily infer relationships among physicochemical properties and ADMET properties and adverse effects based on how new compounds overlap with the space of approved drugs and their targets for new compounds. IDAAPM is coupled with KNIME , a modern data analytics platform to allow data access, data transformation, initial analysis, visualization and predictive modeling. KNIME platform implements a modular approach to workflow management and allows the flexibility to incorporate different tools and also create specialized workflows that are easy to use for automation.
Construction and content
Approved drugs (small molecule and biologics) application information was collected from the FDA resource Drug@FDA. For each drug entry, the standard drug information was collected, including trade names, administration routes, dosage, and approval data. Similarly, adverse effect reports for each drug were taken from FAERS, among them; patient data (demographics and administrative) and drug related data (name, indication, dosage, drug name, route of administration, frequency). Adverse effects are reported using the “preferred terms” (PT) of the medical dictionary for regulatory activities (MedDRA) . MedDRA has a hierarchical structure with five levels: system organ class (SOC), high level group, high level, PT and lowest level. FAERS data are entered in the system by health care professionals and consumers, which can lead to errors and non-normalized data, thus forming substantial barriers for data integration for the purpose of data analysis. In IDAAPM, we have linked the PT to their corresponding 26 SOC to solve typographical errors and the PT difference between MedDRA versions. This produces data ready for mining that are clean, normalized and aggregated into fewer classes.
The two dimensional structure of the approved drugs, molecular descriptors and ADMET properties and adverse effects were collected from DrugBank and cross checked with PubChem, and ChemIDplus. Binding affinities and drug target data were collected from BindingDB. Target information contains target name, target source organism and drugs binding affinity data (such as Ki, IC50 and Kd) with reference to the original publication. The chemical structures are stored in the database using the IUPAC international chemical identifier (InChi key and InChi code) and SMILES (simplified molecular-input line-entry system). Drug structures were checked for potential problems (incorrect structures, salts) and then normalized in the database using their InChi key to avoid duplicate entries. For each compound, external reference to DrugBank, PubChem, IUPHAR and ChEBI were added in order to facilitate cross-linking and cross checking. The overall flowchart depicting the different steps of the database construction with sources, contents and processes is presented in Additional file 1.
Data preparation and integration
Data in IDAAPM was extracted from the resources listed above and supplemented with journal references when available (Additional file 1). First, all FDA approved drugs data were downloaded from Drug@FDA database in text file. Second, a .sql script (Additional file 4) was developed to extract and insert them in IDAAPM. The FAERS database was downloaded entirely into an .xml file, then an R script (Additional file 5) was developed to extract the adverse effects data of all approved drugs. Following this, a .sql script (Additional file 6) was written to insert the data into the IDAAPM database. Next, approved drugs data were downloaded from DrugBank into an .xml file, extracted with an R script (Additional file 7) and inserted into IDAAPM using a .sql script (Additional file 8). Then, PubChem and ChemIDplus were used to manually extract about 50 compound structures and molecular properties missing from DrugBank data. After that, drug-targets bioactivity data were downloaded from BindingDB as a .tsv file. A .sql script (Additional file 9) was developed to extract and insert the corresponding chemical structures, molecular descriptors, ADMET property information, drug target information and binding affinity as well as available literature references into IDAAPM. The SMILES and InChI code were cross-compared to those reported in PubChem and ChEMBL as an additional means to check for errors. Moreover, links to popular databases were also captured, if available. The curating process involved reading scientific articles (abstracts and full texts) then checking data to ensure that the correct drug names and affinity data had been assigned, followed by then manually cross checking the accuracy of data between different sources. A KNIME workflow module was developed to cross check the drug-target bioactivity data from PubChem and CheMBL. Special attention was given to the quality of chemical structures and bioactivity data. Finally, manual checking was performed on each entry as part of a continuous process. The binding affinity data unit of measurement are standardized preferred units of measurements for a given activity type. For instance, Ki, IC50, Kd EC50 are recorded as nM, rather than µM or mM. This enables the user to easily compare data across different assays. We ensure that all bioactivity data in the database has been referenced. If a user finds a specific compound to be useful, they may follow the links to view literature available on that compound. Protein targets are further classified as receptor, enzyme, transporter, channel, kinase and others. This also allows data to be queried at a higher level.
Summary of IDAAPM content
4849 New drugs
IDAAPM is freely accessible via an online graphical user interface at (http://idaapm.helsinki.fi). The database browser was organized using a flask framework, java script, cascading style sheet and Jinja2 applications (Additional file 11A). The IDAAPM server was built with gunicorn, nginx and PostgreSQL 9.3.12, installed on Ubuntu 14.04.4. The user interface allows users to search the database by drug area, route of administration, target class, small molecules or biologics. Search with one of the above criteria allows retrieval of all matching drugs with their approval information, molecular descriptors, 2D structures, targets (Additional file 11B) and related bioactivity as well as adverse effect frequency and links to the literature references from which the data originated (Additional file 11C). From the download page, users can download the entire database as TSV/CSV format or a specific subset (small molecules/biologics) as well as molecular structures (SMILES format). A database dump is also available for download enabling users to install their own local copy of the database.
Finally, and most importantly, IDAAPM can be exploited through KNIME workflows (can be downloded from http://idaapm.helsinki.fi) connected to the database. The KNIME access (Fig. 4a) workflow enables the database to be queried by drug name, active ingredient, FDA application number, SMILES, sub-structural and structural similarity search (Additional file 12). The user has the possibility to build complex queries to search the database. IDAAPM provides different levels of ADMET properties and adverse effects search. At the first level, the search can be performed by (1) choosing to view all drug information, (2) searching a specific compound using drug name or active ingredient or (3) compound searching by drug area. At the second level, searching can be performed using drug area, route of administration and drug target class to further filter the results. More specific searches can also be performed using FDA application number, brand name, and active ingredient or drug area. Similarly, results obtained can be later exported as .sdf files (Fig. 4b). Compound searching can be filtered by drug area as well, such as gastrointestinal, Cardiovascular, Diabetes Drugs and Endocrinology, Eye, Hematology and so on. At the lowest level, the search criteria set up in the two previous levels can be completed with more additional data, using the check boxes in the last section (Additional file 12).
Clean, structured and high quality data stored in a relational database resource can facilitate computational predictive modeling, thus allowing for new information to be inferred by computational analyses. Data mining using resources like IDAAPM can be employed to understand, for example, target function or the promiscuous nature of compounds binding to specific types of proteins. We can infer the relationships between targets and their drugs in order to characterize the molecular properties of compounds with specific ADMET properties and adverse effects. For a new compound or target, IDAAPM can be exploited in regard to probable mode of administration and status (Fig. 2a), target class and drug area (Fig. 2b) as well as adverse effect and the drug area of current drugs in the database (Fig. 3a).
IDAAPM enables researchers to perform data analysis and data mining from safe drugs data and to identify the space of similar compounds and similar targets. This is particularly important for prediction of possible ADMET properties or adverse effects of new drug molecules. Furthermore, this will allow the prospect of in silico approaches to be used for drug repurposing through the integration of knowledge from IDAAPM.
Three examples of usage are presented. In the first example, IDAAPM usage coupled with KNIME capabilities is presented in Fig. 4c, d. First, on Fig. 4c, for a set of compounds selected from IDAAPM, a distance matrix can be calculated and used to characterize the chemical space (heat map and 2D/3D scatter plot) as well as cluster analysis (hierarchical clustering) of the compounds selected by querying IDAAPM (Fig. 4c). Then, on Fig. 4d, a structure similarity towards IDAAPM compounds is exemplified to identify the most similar or dissimilar compounds using for example Tanimoto similarity coefficient (Fig. 4d). As a result, a 2D/3D structural similarity matrix is obtained by computing Tanimoto distance values for all pairs of the compounds, included as a single column containing distance vector values.
A third example of usage is provided by a workflow (in Fig. 4e) used to build predictive classification models inside KNIME from bioactivity data, ADMET, adverse effects, or molecular descriptors selected from IDAAPM is demonstrated. Data are uploaded from .sdf files exported from a search result made on IDAAPM. As seen in this example, the data are first normalized, then separated into training and test sets. This is followed by model construction, either using K-nearest neighbors or the support vector machine method. The stability of the trained model can be verified through cross validation during the process and its predictive ability can be estimated using the external test set. The scorer node reports a confusion matrix and the related accuracy statistic of generated models.
IDAAPM offers structured and manually curated data on approved drugs, physicochemical properties, ADMET and adverse effects as well as related target information. It provides measured bioactivities, also structural information, which is essential in predictive modeling. IDAAPM combines detailed information on approved drugs in a single platform integrated with KNIME. The KNIME workflow has been developed to allow for easy access to the safe compound information and further provide the researcher with more opportunity to develop their own custom workflow, depending on their needs. The availability of the data in an easily accessible form will allow researchers in the field to easily use this data as well as allow easy integration with other programs and services. It will provide data from available safe drugs and knowledge for drug discovery and development.
Further data curation, comprehensive data coverage and improvements are planned for subsequent IDAAPM releases, as well as inclusion of additional predictive modeling KNIME workflows. Moreover, we aim to include all compounds in advanced clinical trials, as this is highly relevant in the context of drug discovery. Even though the first release of IDAAPM includes experimental and calculated physico-chemical properties, we aim to include additional molecular properties.
IDAAPM full database and KNIME workflows are freely accessible at http://idaapm.helsinki.fi.
HX, AL and LG conducted to the design of IDAAPM and supervision of the work. The manuscript was written through contributions of all authors. All authors read and approved the final manuscript.
This study was fund by the Drug Discovery and Computational Biology consortium from Biocenter-Finland. The Center for Scientific Computing is thanked for help with computational resources and data storage.
The authors declare that they have no competing interests.
- 13.Hartung T, Hoffmann S (2009) Food for thought … on in silico methods in toxicology. Altex 26(3):155–166Google Scholar
- 15.Modi S, Li J, Malcomber S, Moore C, Scott A, White A, Carmichael P (2012) Integrated in silico approaches for the prediction of Ames test mutagenicity. J Comput Aided Mol Des 26(9):1017–1033Google Scholar
- 22.Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA et al (2016) The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44(D1):D1054–D1068CrossRefGoogle Scholar
- 24.Miller MA, Hazard GF, Hudson VW, Hilt C, Fang J, Mayer D, Callahan L (2003) ChemIDplus: a free, web-based portal to a variety of compound-based information. Abstr Pap Am Chem Soc 226:U305Google Scholar
- 25.U.S. Food and Drug Administration Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
- 26.Ahmad SR, Goetsch RA, Marks NS (2005) Spontaneous reporting in the United States. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, UK, pp 135–159Google Scholar
- 27.Harpaz R, Haerian K, Chase HS, Friedman C (2010) Statistical mining of potential drug interaction adverse effects in FDA’s spontaneous reporting system. AMIA Annu Symp Proc 2010:281–285Google Scholar
- 31.Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P (2010) A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 6. doi: 10.1038/msb.2009.98
- 33.Berthold MR, Cebron N, Dill F, Di Fatta G, Gabriel TR, Georg F, Meinl T, Ohl P, Sieb C, Wiswedel B (2006) Knime: The konstanz information miner. In: 4th international industrial simulation conference 2006, pp 58–61Google Scholar
- 34.Giannangelo K (2006) Principles to guide maintenance of classifications. In: Reichert A, Mihalas G, Stoicu-Tivadar L et al (eds) Proceedings of the EFMI special topic conference. Integrating biomedical information: from E-cell to E-patient, Timisoara, Romania, 6–8 April 2006. AKA-Verlag, Berlin, pp 293–297Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.